Recently, the clinical study results of Mazdutide, the medicine for blood glucose reduction and weight loss developed by Innovent Biologics (Hangzhou) Co., Ltd., were published in the international top academic journal Nature.

Mazdutide is the only approved GCG/GLP-1 natural dual-target medicine for blood glucose reduction and weight loss that is the first one in the world. Its therapeutic effect is superior to that of Semaglutide reputed as the foreign star product. It breaks the long-standing dependence of domestic market on imported medicine.

At present, Mazdutide has been approved in China, and it is planned to launch the clinical trial targeting adolescent obesity.